Olaparib Maintenance Fails to Significantly Prolong Survival in Ovarian Cancer

Share this content:
Among patients with ovarian cancer, olaparib maintenance monotherapy failed to significantly prolong overall survival.
Among patients with ovarian cancer, olaparib maintenance monotherapy failed to significantly prolong overall survival.

Among patients with BRCA-mutant platinum-sensitive recurrent serous ovarian cancer, olaparib maintenance monotherapy after platinum-based chemotherapy failed to significantly prolong overall survival, despite improving progression-free survival, according to a study published in The Lancet Oncology.1

Previously reported data demonstrate that maintenance monotherapy with olaparib significantly prolongs progression-free survival, in contrast with placebo, in this patient population. After more than 5 years of follow-up, researchers evaluated overall survival, a secondary endpoint of the study.

Among the 265 patients randomly assigned to olaparib or placebo, median overall survival was 29.8 months (95% CI, 26.9-35.7) for olaparib, compared with 27.8 months (95% CI, 24.9-33.7) for placebo (hazard ratio [HR], 0.73; 95% CI, 0.55-0.96; P = .025).

Among the 136 patients with deleterious BRCA mutations, median overall survival was 34.9 months (95% CI, 29.2-54.6) and 30.2 months (95% CI, 23.1-40.7) with olaparib and placebo, respectively (HR, 0.62; 95% CI, 0.41-0.94; P = .025).

RELATED: Mortality From Ovarian Cancer on Decline in the West

In those with BRCA wild-type, median overall survival was 24.5 months (95% CI, 19.8-35.0) for those treated with olaparib, versus 26.6 months (95% CI, 23.1-32.5) for those treated with placebo (HR, 0.83; 95% CI, 0.55-1.24; P = .37).

The most common grade 3 or worse adverse events in the olaparib arm were fatigue and anemia. No new safety signals were observed; adverse events occurred mostly during the first 2 years of treatment.                              


  1. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Sep 8. doi: 10.1016/S1470-2045(16)30376-X [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs